National research team targets glioblastoma
MAY 31, 2019 — Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and is characterized by its infiltrative and often fatal progression. The strikingly poor survival for patients with GBM of 14-16 months following diagnosis is due in part to limited early detection methods and an absence of effective treatment options. Funding […]
BIOMARK ANNOUNCES NEW PATENT GRANTED IN UNITED STATES
Vancouver, British Columbia – (May 30th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been recently granted in United States. Rashid Ahmed, President and CEO, says, “Granting of this patent expands and strengthens […]
BIOMARK’S ABSTRACT FOR 2019 ASCO ONLINE PUBLICATION
Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 activity. Sub-category: Circulating Biomarkers Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) Meeting: 2019 ASCO Annual Meeting Abstract No: e14536 Citation: J Clin Oncol 37, 2019 (suppl; abstr e14536) Author(s): Andrew W. Maksymiuk, Paramjit S. Tappia, Bram Ramjiawan, Nazrina Khatun, Rahnuma Parveen, Rashiduzzaman Ahmed, Gina Huang, Rashid Bux Ahmed, […]
REVISION ON TOTAL FUNDING SECURED BY BIOMARK AND ITS TEAM OF COLLABORATORS ON CHRP APPLICATION
Vancouver, British Columbia – (May 1st, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) would like to correct its news release dated on April 17th, 2019 announcing the approval of the application entitled “Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma”, submitted […]
BIOMARK ANNOUNCES THE PRIVATE PLACEMENT
Vancouver, British Columbia – (April 9th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 2,000,000 Units at a price of $0.10 to raise gross proceeds of up to $200,000. Each Unit is composed […]
BIOMARK CLOSES THE PRIVATE PLACEMENT OFFERING
April 16th, 2019 – Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of April 9th, 2019, it has closed the non-brokered private placement for gross proceeds of $200,000.00 wherein BioMark issued 2,000,000 units at a price […]
BIOMARK AND ITS TEAM OF COLLABORATORS SECURE CHRP FUNDING
Vancouver, British Columbia – (April 17, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that its application entitled “Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma”, submitted to the Collaborative Health Research Projects funding opportunity, has been approved. […]
BIOMARK’S ABSTRACT ACCEPTED FOR 2019 ASCO ONLINE PUBLICATION
Vancouver, British Columbia – (April 3, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) under Dr. Andrew Maksymiuk was accepted for online publication. The abstract was titled “Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 […]
Cancer risk in families
If you have family members with cancer, you may wonder if you are at risk of developing it too (if it “runs in the family”). Sometimes a gene mutation that can cause cancer is passed on to you by your parents (inherited). Cancers caused by inherited gene mutations are called inherited cancers. And sometimes cancer […]
About Glioblastoma (GBM)
Overview Tumour Group: Gliomas WHO Grade: Grade IV Prevalence/Incidence: The incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumours and 50 to 60 per cent of astrocytic tumours. GBMs increase in frequency with age, and affect […]